Study to assess the efficacy and tolerability of Antistax® film-coated tablets in patients with chronic venous insufficiency (CVI, Clinical condition, Etiology, Anatomic location, Pathophysiology (CEAP) Classification: Clinical Class 3, or 4a)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
245
Change from baseline in limb volume determination
water displacement method
Time frame: Baseline, day 84
Changes in limb volume determination
water displacement method
Time frame: Baseline, day 21 and day 42
Changes in the calf circumference
in centimeters
Time frame: Baseline, at day 21, 42 and 84
Changes in the ankle circumference
in centimeters
Time frame: Baseline, at day 21, 42, and 84
Changes in the subjective symptoms of CVI measured by Visual Analogue Scales (VAS)
Time frame: Baseline, at day 21, 42, and 84
Global assessment of efficacy by the patient on a 4-point verbal rating scale (VRS)
Time frame: day 84
Global assessment of efficacy by the investigator on a 4-point VRS
Time frame: day 84
Global assessment of tolerability by the patient on a 4-point VRS
Time frame: day 84
Global assessment of tolerability by the investigator on a 4-point VRS
Time frame: Day 84
Number of patients with adverse events
Time frame: up to 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of patients with clinically significant changes in laboratory values
Time frame: Baseline, week 12
Number of patients with clinically significant changes in vital signs (Blood Pressure (BP), Pulse Rate (PR))
Time frame: Baseline, up to 12 weeks